相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Quantification and discriminative power of 18F-FE-PE2I PET in patients with Parkinson's disease
Aline Delva et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease
Diane Stephenson et al.
JOURNAL OF PARKINSONS DISEASE (2019)
Striatal DAT SPECT: Caveat Emptor!
Joel S. Perlmutter et al.
MOVEMENT DISORDERS (2019)
A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein
Kalpana M. Merchant et al.
JOURNAL OF PARKINSONS DISEASE (2019)
Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECTa clinical comparison
Susanna Jakobson Mo et al.
EJNMMI RESEARCH (2018)
Reliability of volumetric and surface-based normalisation and smoothing techniques for PET analysis of the cortex: A test-retest analysis using [11C] SCH-23390
Granville J. Matheson et al.
NEUROIMAGE (2017)
Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients
Ida Sonni et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Quantitative Analysis of 18F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4′-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease
Patrik Fazio et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Longitudinal follow-up of SWEDD subjects in the PRECEPT Study
Kenneth Marek et al.
NEUROLOGY (2014)
Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies
Florian Krismer et al.
PARKINSONISM & RELATED DISORDERS (2014)
Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT
Martin Schain et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
An efficient one-step radiosynthesis of [18F]FE-PE2I, a PET radioligand for imaging of dopamine transporters
Vladimir Stepanov et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2012)
SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0
David S. W. Djang et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Quantification of Dopamine Transporter in Human Brain Using PET with 18F-FE-PE2I
Takeshi Sasaki et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Simplified quantification and whole-body distribution of [18F]FE-PE2I in nonhuman primates: prediction for human studies
Andrea Varrone et al.
NUCLEAR MEDICINE AND BIOLOGY (2012)
The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration
Jeffrey L. Cummings et al.
BRAIN (2011)
Kinetic Analysis and Quantification of the Dopamine Transporter in the Nonhuman Primate Brain with C-11-PE2I and F-18-FE-PE2I
Andrea Varrone et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Clinical Progression in Parkinson Disease and the Neurobiology of Axons
Hsiao-Chun Cheng et al.
ANNALS OF NEUROLOGY (2010)
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms
Maria C. Rodriguez-Oroz et al.
LANCET NEUROLOGY (2009)
In Vitro Autoradiography and In Vivo Evaluation in Cynomolgus Monkey of [18F]FE-PE2I, a New Dopamine Transporter PET Radioligand
Andrea Varrone et al.
SYNAPSE (2009)
Dopamine transporter imaging with [123I]FP-CIT SPECT:: potential effects of drugs
Jan Booij et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
Ira Shoulson et al.
NEUROLOGY (2007)
Disease-related and drug-induced changes in dopamine transporter expression might undermine the reliability of imaging studies of disease progression in Parkinson's disease
A Winogrodzka et al.
PARKINSONISM & RELATED DISORDERS (2005)
[123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease
A Winogrodzka et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2003)
Dopamine transporter: Basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism
GR Uhl
MOVEMENT DISORDERS (2003)
Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain
B Fischl et al.
NEURON (2002)
[123I]β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression
K Marek et al.
NEUROLOGY (2001)
Rate of progression in Parkinson's disease:: A 6-[18F]fluoro-L-dopa PET study
E Nurmi et al.
MOVEMENT DISORDERS (2001)
分享论文
